Research article · 22 Jul 2022
Conference abstractPublished 8 Dec 2016
Fluorescence Angiography Assisted Lower Extremity Amputation
Madigan Army Medical Center United States
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction Wound complications within the immediate perioperative period for lower extremity amputation at any level ranges from 13 to 79%. More than half of readmissions following TMA, BKA and AKA, specifically, are due to wound related complications . Although multiple risk factors contribute to suture line complications a major factor is inadequate perfusion to the suture line. Fluorescence angiography allows for intraoperative assessment of suture line perfusion and facilitates intraoperative modifications to ensure adequate perfusion to the suture line exists prior to leaving the operating room. Materials and Methods Fluorescence angiography was used in 27 cases (26 patients) requiring lower extremity amputation ranging from digital to above knee amputation to assess microperfusion of the flaps after creation and closure. Results of this imaging was used to guide the need for modification to ensure adequate perfusion to the amputation site prior to leaving the operating room.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2019
Diagnosis and treatment of the postnecrotic phenomenon such as putrefaction and omificafion of the lower extremities in diabetic patients avoiding amputations
Review article · 25 Jun 2014
Lower Extremity Amputation in People with Diabetes as a Marker of Quality of Diabetes Care
Conference abstract · 2023
Prevalence and determinants of lower extremity amputations among type I and type II diabetic patients: A multi-center -based study
Research article · 24 Jun 2022
Risk Factors Associated with lower extremity amputation in diabetic patients with neuropathic ulcerations of the foot treated with human recombinant Epidermal Growth factor (Heberprot P).
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Charles A Andersen”
